Cardiovascular disease (triglyceride lowering)

Stage (next event)

Expected Date

Quarterly Sales (Approved)

February 26, 2021 (Est)

Catalyst Info & Data Links


  • Studies suggest that EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity.

  • FDA Drug Label (slide 5, section 12.1)


Updated by EJV (Prior update by HC 11/20/20)

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See what the community is saying - click to see full post

AMRN Litigation Update - 5/19/20 BIO Brief

AMRN - Near-Term Price Acton Depends on Breadth of Label, but Acquisition Chatter and Quarterly Resu

Amarin's U.S. Patent Protection For Vascepa

Congrats Amarin for Major Breakthrough in Treating Cardiovascular Disease

AMRN; a Q3 Pick and Possible Run-Up

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon